Holdings
Roundhill GLP-1 & Weight Loss ETF
As of Jun 30, 2026, Roundhill GLP-1 & Weight Loss ETF reported 23 positions worth US$52.2M. Largest: Novo Nordisk A/s Class B, Eli Lilly And Company and Pfizer, Inc. What it bought and sold, with each filing.
| Company | Shares | Value as reported | Change | As of |
|---|---|---|---|---|
| Novo Nordisk A/s Class B | 148K | US$7.01M | −31,495 | Jun 30, 2026 |
| Eli Lilly And Company | 5,722 | US$6.86M | −3,281 | Jun 30, 2026 |
| Pfizer, Inc. | 143K | US$3.45M | +4,970 | Jun 30, 2026 |
| Kailera Therapeutics, Inc. | 153K | US$3.36M | new | Jun 30, 2026 |
| Viking Therapeutics, Inc. | 81,186 | US$3.17M | −2,383 | Jun 30, 2026 |
| Cspc Pharmaceutical Group Limited | 3.24M | US$2.88M | +1.94M | Jun 30, 2026 |
| Chugai Pharmaceutical Co., Ltd. | 52,600 | US$2.44M | +19,800 | Jun 30, 2026 |
| Ascletis Pharma, Inc. | 1.69M | US$2.27M | +553K | Jun 30, 2026 |
| Zealand Pharma A/s | 47,873 | US$2.12M | +7,188 | Jun 30, 2026 |
| Amgen Inc. | 5,750 | US$2.08M | −12 | Jun 30, 2026 |